Memantine Pilot Study for Cognitive Protection in Pediatric Brain Tumor Patients Undergoing Radiation
A pilot study is underway to evaluate memantine as a neuro-protective agent in children receiving cranial radiation therapy for localized brain tumors.
Phase III
National Cancer Institute
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing pilot study of memantine as a neuro-protective agent in pediatric patients undergoing cranial radiation therapy could redefine treatment protocols in pediatric oncology. If successful, it may lead to significant advancements in cognitive care for children with brain tumors, influencing future drug development and clinical practices.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor participation rates, adherence to memantine, and cognitive assessment completion as key indicators of study feasibility and potential efficacy.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.